Analysts expect GTx, Inc. (NASDAQ:GTXI) to announce earnings per share (EPS) of ($0.30) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for GTX’s earnings, with estimates ranging from ($0.44) to ($0.16). GTX posted earnings of ($0.53) per share in the same quarter last year, which would suggest a positive year over year growth rate of 43.4%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that GTX will report full year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.95) to ($1.29). For the next financial year, analysts forecast that the business will post earnings of ($1.81) per share, with EPS estimates ranging from ($1.84) to ($1.78). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover GTX.
GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43).
Several research firms recently issued reports on GTXI. BidaskClub lowered GTX from a “hold” rating to a “sell” rating in a report on Saturday, June 30th. Zacks Investment Research upgraded GTX from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine lowered GTX from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Robert W. Baird lowered GTX from an “outperform” rating to a “neutral” rating and set a $17.00 target price on the stock. in a report on Friday, September 21st. Finally, Stifel Nicolaus lowered GTX from a “buy” rating to a “hold” rating in a report on Friday, September 21st. Five investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and a consensus price target of $31.00.
GTXI traded down $0.12 on Monday, hitting $1.79. 4,938,300 shares of the company were exchanged, compared to its average volume of 680,261. GTX has a 12 month low of $1.32 and a 12 month high of $25.60. The firm has a market capitalization of $37.75 million, a PE ratio of -1.05 and a beta of 1.67.
In other GTX news, VP Diane C. Young sold 2,049 shares of the company’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $14.70, for a total value of $30,120.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 40.90% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp raised its stake in GTX by 222.4% in the second quarter. Northern Trust Corp now owns 60,296 shares of the biopharmaceutical company’s stock valued at $923,000 after buying an additional 41,591 shares during the period. Bank of New York Mellon Corp raised its stake in GTX by 31.8% in the second quarter. Bank of New York Mellon Corp now owns 30,943 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 7,473 shares during the period. Point72 Asset Management L.P. raised its stake in GTX by 57.6% in the second quarter. Point72 Asset Management L.P. now owns 170,250 shares of the biopharmaceutical company’s stock valued at $2,607,000 after buying an additional 62,250 shares during the period. Renaissance Technologies LLC raised its stake in GTX by 4.8% in the second quarter. Renaissance Technologies LLC now owns 76,695 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 3,500 shares during the period. Finally, Citadel Advisors LLC bought a new stake in GTX in the second quarter valued at approximately $296,000. Hedge funds and other institutional investors own 28.38% of the company’s stock.
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Featured Story: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.